Rara

NFT EXPEDITION TOKENS FOR WIND-POWERED ARCTIC JOURNEY TO DROP

Retrieved on: 
Wednesday, April 13, 2022
Travel, Clothing, Red Bull, NFT, Carbon, Climate change, Barents Sea, Weather, DAO, Non-fungible token, Philosophy, Rara, Aerial, Jones, Kodak, Whaling, Cryptocurrency, The New York Times

TROMSØ, Norway, April 13, 2022 /PRNewswire/ -- On April 18th, 2022, a group of Swiss and American explorers will untie from Old Harbor in Tromsø to embark on a carbon-neutral two-week exploratory journey across the Barents Sea. Guided by legendary skipper Rasmus Jacobsen, the crew will sail the S/V Linden, Scandinavia's largest sailing vessel, to the Svalbard Archipelago, one of earth's most fragile and at-risk ecosystems. The wind-powered three-masted schooner will allow the group to move quietly, employing a "leave-no-trace" philosophy, entering a region controlled by no nation, where polar bears, bearded seals, and beluga whales rule.

Key Points: 
  • Simultaneous with the group's departure will be the release of the world's first exclusive NFT auction of Expedition Tokens, designed by Rara Data, an Australia-based company that recently produced (and sold out) NFTs for several international brands.
  • The carbon footprint of the expedition will be offset by Aerial, an official partner for the expedition.
  • The Svalbard expedition marks the first journey in a series of Expedition Token projects, as creators embark on human-powered journeys to bear witness to and make a record of at risk-ecosystems across the planet.
  • Expedition Token is a decentralized autonomous organization (DAO) that partners with elite expedition teams built out of frontline scientists, artists, and seasoned adventurers.

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Retrieved on: 
Thursday, August 5, 2021
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Roche, APL, Venetoclax, Gene, Safety, LinkedIn, Clinical trial, MDS, Compte rendu, Acute myeloid leukemia, Annual report, Acute promyelocytic leukemia, Twitter, CDK, ESMO, ID, Immunotherapy, Research, Genome, G&A, Lists of people executed in the United States, Security (finance), Lung, Investor, BRAF, Azacitidine, Congress, Fulvestrant, Workforce, Cyclin-dependent kinase 7, Rara, Breast, Arsenic trioxide, Initiate, Nasdaq, U.S. Securities and Exchange Commission, Webcast, Freedom, GBT, Private Securities Litigation Reform Act, Kol, Hematology, Government, AML, Selective estrogen receptor degrader, Patient, COVID-19, Ovarian cancer, Colorectal cancer, Phase 1, Histology, Pharmaceutical industry, Medical device

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.
  • Research and development expenses were $25.8 million for the first quarter of 2021, as compared to $14.8 million for the second quarter of 2020.
  • General and administrative (G&A) expenses were $5.5 million for the second quarter of 2021, as compared to $5.1 million for the second quarter of 2020.
  • ET to discuss these second quarter 2021 financial results and provide a corporate update.

Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer

Retrieved on: 
Thursday, August 5, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Lung, Cancer, BRAF, Clinical trial, U.S. Securities and Exchange Commission, Freedom, Compte rendu, Private Securities Litigation Reform Act, Acute myeloid leukemia, Annual report, Government, Roche, Acute promyelocytic leukemia, Congress, Patient, COVID-19, Twitter, Workforce, Society, Cyclin-dependent kinase 7, Rara, Gene, Colorectal cancer, Rb, Immunotherapy, Histology, CRC, DNA, Arsenic trioxide, Safety, Genome, LinkedIn, Nasdaq, Security (finance), Pharmaceutical industry, Vaccine

Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.

Key Points: 
  • Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.
  • Notably, this trial marks the first clinical investigation of a CDK7 inhibitor with an immunotherapy, and we look forward to working with Roche to evaluate the potential of this novel combination in patients with BRAF-mutant colorectal cancer.
  • Under the terms of the agreement, Roche will sponsor and conduct the Phase 1/1b study to evaluate the safety, tolerability and preliminary efficacy of the combination and will assume all costs associated with the study.
  • In exchange for providing SY-5609, Syros will receive access to the data on SY-5609 in combination with atezolizumab.

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

Retrieved on: 
Saturday, December 5, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Chemical compounds, Organic compounds, Orphan drugs, Heterocyclic compounds, Antineoplastic drugs, Breakthrough therapy, Chloroarenes, Sulfonamides, Venetoclax, Azacitidine, Rara

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting.
  • As of October 1st, 51 newly diagnosed unfit AML patients, including both RARA-positive and RARA-negative patients, were eligible for a safety analysis.
  • As of October 1st, 28 RARA-positive R/R AML patients were eligible for safety analysis and 21 were evaluable for clinical response.
  • In addition, Syros plans to advance SY-1425 in combination with venetoclax and azacitidine in RARA-positive newly diagnosed unfit AML patients.